

OUTPATIENT CASE MANAGEMENT OF DRUG RESISTANT TB

WD4099

PROGRAM DESCRIPTION: This course is designed for participants who may be involved with the care and treatment of an outpatient with drug-resistant tuberculosis. Through the presentation, participants will be able to describe three types of drug-resistance, list two implications in managing drug-resistant patients as outpatients, identify three side-effects that warrant close monitoring, and identify three characteristics of those at risk for drug resistance.

OBJECTIVES:

At the conclusion of the session, the participant will be able to:

1. Describe the 3 types of drug resistance
2. List at least 2 implications for public health programs in managing drug-resistant patients as outpatients
3. Identify 3 side effects that warrant close monitoring of outpatients on non-first line anti-tuberculous medications
4. Identify 3 characteristics of those at risk for drug resistance

Faculty/Credentials

Elizabeth Foy, BSN, RN

TB and Hansen's Disease Nurse Administrator, Texas
Department of State Health Services, TB & Refugee
Health Services Branch

Quratulain Kizilbash, MD, MPH

Medical Director, Texas Department of State Health
Services

Rachel Munoz, RN

Nurse Case Manager/Nurse Consultant; Austin/Travis
County Health Department

Mary Ann Rodriguez, MD

Medical Director, Austin Public Health

Barbara Seaworth, BS, MD, FIDSA, FACP

Medical Director and Professor of Medicine,
Heartland National TB Center, UT Health Northeast

ORIGINATION DATE: September 1, 2018
RENEWAL DATE:
EXPIRATION DATE: September 1, 2020
URL: to be determined
HARDWARE/SOFTWARE: Computer Hardware; Internet connection; web browser
MATERIALS: None
TARGET AUDIENCE: Physicians, Registered Nurses, Advanced Practice Nurses, Licensed Practical/Vocational Nurses, Medical Assistants, Physician Assistants, and other Health Educators
PREREQUISITES: None
FORMAT: Web on demand
CONTACT INFORMATION: Office of Jessica Quintero, M.Ed, (210) 531-4568

ACCREDITATION STATEMENTS:

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

The Centers for Disease Control and Prevention designates this **enduring material** for a maximum of **1.25 AMA PRA Category 1 Credits™**. Physicians *should claim only the credit commensurate with the extent* of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity provides **1.2** contact hours.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer **0.1** CEU's for this program.

DISCLOSURE: In compliance with continuing education requirements, all presenters must disclose any financial or other associations with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters as well as any use of unlabeled product(s) or product(s) under investigational use.

CDC, our planners, content experts, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dr. Rodriguez' discussion on Outpatient Case Management of Drug Resistance. She will be discussing clofazimine that has in vitro activity against Mycobacterium tuberculosis without much in vivo data and is generally reserved for cases with few other options and Bedaquiline that is only used when an effective treatment regimen cannot otherwise provided.

The Centers for Disease Control and Prevention and Heartland National TB Center are jointly providing the CNE for this activity.

CDC did not accept commercial support for this continuing education activity.

Instructions for Obtaining Continuing Education (CE)

In order to receive continuing education (CE) for *WD4099 Outpatient Management of Drug Resistant TB* please visit [TCEO](#) and follow these [9 Simple Steps](#) before 9/01/2020.

Complete the activity

Complete the Evaluation at www.cdc.gov/GetCE

Pass the posttest at **75%** at www.cdc.gov/GetCE

FEES: No fees are charged for CDC's CE activities.